New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment
- PMID: 22825583
- PMCID: PMC3432735
- DOI: 10.1158/1078-0432.CCR-11-2375
New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment
Abstract
Malignant pleural mesothelioma (MPM) is a highly lethal cancer with limited therapeutic options. Recent work has focused on the frequent somatic inactivation of two tumor suppressor genes in MPM-NF2 (Neurofibromatosis type 2) and the recently identified BAP1 (BRCA associated protein 1). In addition, germline mutations in BAP1 have been identified that define a new familial cancer syndrome, which includes MPM, ocular melanoma, and other cancers. These recent advances may allow screening of high-risk individuals and the development of new therapies that target key pathways in MPM.
©2012 AACR.
Figures
References
-
- Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005. Cancer Causes Control. 2009;20:935–44. - PubMed
-
- Krug LM. An overview of chemotherapy for mesothelioma. Hematol Oncol Clin North Am. 2005;19:1117–36. vii. - PubMed
-
- Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995;55:1227–31. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
